Eric Sun
Personal Details
First Name: | Eric |
Middle Name: | |
Last Name: | Sun |
Suffix: | |
RePEc Short-ID: | psu228 |
| |
Affiliation
(in no particular order)
University of Chicago--Pritzker School of Medicine
http://pritzker.bsd.uchicago.edu/Chicago, IL
RAND
Santa Monica, California (United States)http://www.rand.org/
RePEc:edi:randdus (more details at EDIRC)
Research output
Jump to: Working papers Articles ChaptersWorking papers
- Tomas J. Philipson & Eric C. Sun & Dana Goldman, 2009.
"The Effects of Product Liability Exemption in the Presence of the FDA,"
NBER Working Papers
15603, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun & Dana Goldman, 2010. "The Effects of Product Liability Exemption in the Presence of the FDA," NBER Chapters, in: Regulation vs. Litigation: Perspectives from Economics and Law, pages 137-163, National Bureau of Economic Research, Inc.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009.
"An Economic Evaluation of the War on Cancer,"
NBER Working Papers
15574, National Bureau of Economic Research, Inc.
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
- Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun, 2008. "The Value of Life in General Equilibrium," NBER Working Papers 14157, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun, 2007.
"Is the Food and Drug Administration Safe and Effective?,"
NBER Working Papers
13561, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
Articles
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010.
"An economic evaluation of the war on cancer,"
Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.
- Sun Eric & Jena Anupam B & Lakdawalla Darius & Reyes Carolina & Philipson Tomas J & Goldman Dana, 2010. "The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000," Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-22, February.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Tomas Philipson & Anupam B. Jena & Eric Sun, 2007. "The institute of medicine report on the FDA: where is the science?," Health Economics, John Wiley & Sons, Ltd., vol. 16(3), pages 219-221, March.
Chapters
- Tomas J. Philipson & Eric Sun & Dana Goldman, 2010.
"The Effects of Product Liability Exemption in the Presence of the FDA,"
NBER Chapters, in: Regulation vs. Litigation: Perspectives from Economics and Law, pages 137-163,
National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric C. Sun & Dana Goldman, 2009. "The Effects of Product Liability Exemption in the Presence of the FDA," NBER Working Papers 15603, National Bureau of Economic Research, Inc.
Citations
Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.Working papers
- Tomas J. Philipson & Eric C. Sun & Dana Goldman, 2009.
"The Effects of Product Liability Exemption in the Presence of the FDA,"
NBER Working Papers
15603, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun & Dana Goldman, 2010. "The Effects of Product Liability Exemption in the Presence of the FDA," NBER Chapters, in: Regulation vs. Litigation: Perspectives from Economics and Law, pages 137-163, National Bureau of Economic Research, Inc.
Cited by:
- Pagano, Marco & Polo, Michele & Immordino, Giovanni, 2009.
"Incentives to Innovate and Social Harm: Laissez-Faire, Authorization or Penalties?,"
CEPR Discussion Papers
7280, C.E.P.R. Discussion Papers.
- Giovanni Immordino & Marco Pagano & Michele Polo, 2009. "Incentives to Innovate and Social Harm:Laissez-Faire, Authorization or Penalties?," Working Papers 349, IGIER (Innocenzo Gasparini Institute for Economic Research), Bocconi University.
- Immordino, Giovanni & Pagano, Marco & Polo, Michele, 2011. "Incentives to innovate and social harm: Laissez-faire, authorization or penalties?," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 864-876, August.
- Immordino, Giovanni & Pagano, Marco & Polo, Michele, 2011. "Incentives to innovate and social harm: Laissez-faire, authorization or penalties?," Journal of Public Economics, Elsevier, vol. 95(7), pages 864-876.
- Giovanni Immordino & Marco Pagano & Michele Polo, 2009. "Incentives to Innovate and Social Harm: Laissez-Faire, Authorization or Penalties?," CSEF Working Papers 220, Centre for Studies in Economics and Finance (CSEF), University of Naples, Italy.
- Schwartzstein, Joshua & Shleifer, Andrei, 2013.
"An Activity-Generating Theory of Regulation,"
Scholarly Articles
27814564, Harvard University Department of Economics.
- Joshua Schwartzstein & Andrei Shleifer, 2013. "An Activity-Generating Theory of Regulation," Journal of Law and Economics, University of Chicago Press, vol. 56(1), pages 1-38.
- Joshua Schwartzstein & Andrei Shleifer, 2009. "An Activity-Generating Theory of Regulation," NBER Working Papers 14752, National Bureau of Economic Research, Inc.
- Joshua Schwartzstein & Andrei Shleifer, "undated". "An Activity-Generating Theory of Regulation," Working Paper 19524, Harvard University OpenScholar.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009.
"An Economic Evaluation of the War on Cancer,"
NBER Working Papers
15574, National Bureau of Economic Research, Inc.
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010. "An economic evaluation of the war on cancer," Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
Cited by:
- Frank R. Lichtenberg, 2014.
"Has Medical Innovation Reduced Cancer Mortality?,"
CESifo Economic Studies, CESifo Group, vol. 60(1), pages 135-177.
- Frank R. Lichtenberg, 2010. "Has medical innovation reduced cancer mortality?," NBER Working Papers 15880, National Bureau of Economic Research, Inc.
- Kyle, Margaret & Dubois, Pierre, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality," CEPR Discussion Papers 11487, C.E.P.R. Discussion Papers.
- Tomas J. Philipson & Sachin Kamal-Bahl & Anupam B. Jena, 2017. "Defining Value: The Need for a Longer, Broader View," PharmacoEconomics, Springer, vol. 35(7), pages 669-672, July.
- Christoph M Rheinberger & Daniel Herrera-Araujo & James K. Hammitt, 2016.
"The value of disease prevention vs treatment,"
Post-Print
halshs-01626801, HAL.
- Rheinberger, Christoph M. & Herrera-Araujo, Daniel & Hammitt, James K., 2016. "The value of disease prevention vs treatment," Journal of Health Economics, Elsevier, vol. 50(C), pages 247-255.
- Christoph M Rheinberger & Daniel Herrera-Araujo & James K. Hammitt, 2016. "The value of disease prevention vs treatment," PSE-Ecole d'économie de Paris (Postprint) halshs-01626801, HAL.
- Rodrigo Camejo & Clare McGrath & Marisa Miraldo & Frans Rutten, 2014. "Distribution of health-related social surplus in pharmaceuticals: an estimation of consumer and producer surplus in the management of high blood lipids and COPD," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(4), pages 439-445, May.
- Kyle R. Myers, 2022. "Some Tradeoffs of Competition in Grant Contests," Papers 2207.02379, arXiv.org, revised Mar 2024.
- Rebecca Mary Myerson & Reginald Tucker-Seeley & Dana Goldman & Darius N. Lakdawalla, 2019.
"Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?,"
NBER Working Papers
26292, National Bureau of Economic Research, Inc.
- Rebecca M. Myerson & Reginald D. Tucker‐Seeley & Dana P. Goldman & Darius N. Lakdawalla, 2020. "Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?," Journal of Policy Analysis and Management, John Wiley & Sons, Ltd., vol. 39(3), pages 577-604, June.
- Rebecca Myerson & Reginald Tucker-Seeley & Dana Goldman & Darius Lakdawalla, 2019. "Does Medicare Coverage Improve Cancer Detection and Mortality Outcomes?," Working Papers 2019-054, Human Capital and Economic Opportunity Working Group.
- Adam Leive & Thomas Stratmann, 2015. "Do national cancer screening guidelines reduce mortality?," Journal of Population Economics, Springer;European Society for Population Economics, vol. 28(4), pages 1075-1095, October.
- Laura Grigolon & Laura Lasio, 2023. "Biased Beliefs and Stigma as Barriers to Treatment and Innovation Adoption," CRC TR 224 Discussion Paper Series crctr224_2023_277v2, University of Bonn and University of Mannheim, Germany.
- Eric Budish & Benjamin Roin & Heidi Williams, 2013. "Do fixed patent terms distort innovation? Evidence from cancer clinical trials," Discussion Papers 13-001, Stanford Institute for Economic Policy Research.
- Hintermann, Beat & Minke, Matthias, 2018. "The value of extending life at its end: Health care allocation in the presence of learning spillovers," Working papers 2018/15, Faculty of Business and Economics - University of Basel.
- David E. Bloom & Simiao Chen & Michael Kuhn & Mark E. McGovern & Les Oxley & Klaus Prettner, 2017.
"The Economic Burden of Chronic Diseases: Estimates and Projections for China, Japan, and South Korea,"
NBER Working Papers
23601, National Bureau of Economic Research, Inc.
- Bloom, David E. & Chen, Simiao & Kuhn, Michael & McGovern, Mark E. & Oxley, Les & Prettner, Klaus, 2017. "The Economic Burden of Chronic Diseases: Estimates and Projections for China, Japan and South Korea," IZA Discussion Papers 10896, Institute of Labor Economics (IZA).
- Bloom, David E. & Chen, Simiao & Kuhn, Michael & McGovern, Mark & Oxley, Les T. & Prettner, Klaus, 2017. "The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea," Hohenheim Discussion Papers in Business, Economics and Social Sciences 09-2017, University of Hohenheim, Faculty of Business, Economics and Social Sciences.
- Bloom, David E. & Chen, Simiao & Kuhn, Michael & McGovern, Mark E. & Oxley, Les & Prettner, Klaus, 2020. "The economic burden of chronic diseases: Estimates and projections for China, Japan, and South Korea," The Journal of the Economics of Ageing, Elsevier, vol. 17(C).
- Amitabh Chandra & Jonathan S. Skinner, 2011. "Technology Growth and Expenditure Growth in Health Care," NBER Working Papers 16953, National Bureau of Economic Research, Inc.
- Hammitt, James K. & Herrera-Araujo, Daniel & Rheinberger, Christoph, 2016. "The Value of Cancer Prevention vs Treatment," TSE Working Papers 16-628, Toulouse School of Economics (TSE).
- Shafrin, Jason & Skornicki, Michelle & Brauer, Michelle & Villeneuve, Julie & Lees, Michael & Hertel, Nadine & Penrod, John R. & Jansen, Jeroen, 2018. "An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: Does it make a difference?," Health Policy, Elsevier, vol. 122(6), pages 607-613.
- Amitabh Chandra, 2011. "Comment on "The Value of Progress against Cancer in the Elderly"," NBER Chapters, in: Investigations in the Economics of Aging, pages 233-236, National Bureau of Economic Research, Inc.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2013.
"Do firms underinvest in long-term research? Evidence from cancer clinical trials,"
NBER Working Papers
19430, National Bureau of Economic Research, Inc.
- Eric Budish & Benjamin N. Roin & Heidi Williams, 2015. "Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials," American Economic Review, American Economic Association, vol. 105(7), pages 2044-2085, July.
- Dubois, Pierre & Kyle, Margaret, 2016. "The Effects of Pharmaceutical Innovation on Cancer Mortality Rates," TSE Working Papers 16-688, Toulouse School of Economics (TSE).
- Engy Ziedan & Kosali I. Simon & Coady Wing, 2022. "Mortality Effects of Healthcare Supply Shocks: Evidence Using Linked Deaths and Electronic Health Records," NBER Working Papers 30553, National Bureau of Economic Research, Inc.
- Anupam Jena & Casey Mulligan & Tomas J. Philipson & Eric Sun, 2008.
"The Value of Life in General Equilibrium,"
NBER Working Papers
14157, National Bureau of Economic Research, Inc.
Cited by:
- Andr'es Riquelme & Marcela Parada, 2016. "The Value of A Statistical Life in Absence of Panel Data: What can we do?," Papers 1603.00568, arXiv.org.
- Moshe Hazan, 2009. "Longevity and Lifetime Labor Supply: Evidence and Implications," Econometrica, Econometric Society, vol. 77(6), pages 1829-1863, November.
- Eszter Czibor & David Jimenez-Gomez & John A. List, 2019.
"The Dozen Things Experimental Economists Should Do (More of),"
NBER Working Papers
25451, National Bureau of Economic Research, Inc.
- Eszter Czibor & David Jimenez‐Gomez & John A. List, 2019. "The Dozen Things Experimental Economists Should Do (More of)," Southern Economic Journal, John Wiley & Sons, vol. 86(2), pages 371-432, October.
- Eszter Czibor & David Jimenez-Gomez & John List, 2019. "The Dozen Things Experimental Economists Should Do (More of)," Artefactual Field Experiments 00648, The Field Experiments Website.
- Thomas J. Kniesner & W. Kip Viscusi & Christopher Woock & James P. Ziliak, 2010.
"The Value of a Statistical Life: Evidence from Panel Data,"
Center for Policy Research Working Papers
122, Center for Policy Research, Maxwell School, Syracuse University.
- Thomas J. Kniesner & W. Kip Viscusi & Christopher Woock & James P. Ziliak, 2012. "The Value of a Statistical Life: Evidence from Panel Data," The Review of Economics and Statistics, MIT Press, vol. 94(1), pages 74-87, February.
- Hoyt Bleakley, 2009. "Comment on "When Does Improving Health Raise GDP?"," NBER Chapters, in: NBER Macroeconomics Annual 2008, Volume 23, pages 205-220, National Bureau of Economic Research, Inc.
- Mary F. Evans & V. Kerry Smith, 2009.
"Measuring How Risk Tradeoffs Adjust With Income,"
NBER Working Papers
15372, National Bureau of Economic Research, Inc.
- Mary Evans & V. Smith, 2010. "Measuring how risk tradeoffs adjust with income," Journal of Risk and Uncertainty, Springer, vol. 40(1), pages 33-55, February.
- Tomas J. Philipson & Eric Sun, 2007.
"Is the Food and Drug Administration Safe and Effective?,"
NBER Working Papers
13561, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun, 2008. "Is the Food And Drug Administration Safe And Effective?," Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
Cited by:
- Pagano, Marco & Polo, Michele & Immordino, Giovanni, 2009.
"Incentives to Innovate and Social Harm: Laissez-Faire, Authorization or Penalties?,"
CEPR Discussion Papers
7280, C.E.P.R. Discussion Papers.
- Giovanni Immordino & Marco Pagano & Michele Polo, 2009. "Incentives to Innovate and Social Harm:Laissez-Faire, Authorization or Penalties?," Working Papers 349, IGIER (Innocenzo Gasparini Institute for Economic Research), Bocconi University.
- Immordino, Giovanni & Pagano, Marco & Polo, Michele, 2011. "Incentives to innovate and social harm: Laissez-faire, authorization or penalties?," Journal of Public Economics, Elsevier, vol. 95(7-8), pages 864-876, August.
- Immordino, Giovanni & Pagano, Marco & Polo, Michele, 2011. "Incentives to innovate and social harm: Laissez-faire, authorization or penalties?," Journal of Public Economics, Elsevier, vol. 95(7), pages 864-876.
- Giovanni Immordino & Marco Pagano & Michele Polo, 2009. "Incentives to Innovate and Social Harm: Laissez-Faire, Authorization or Penalties?," CSEF Working Papers 220, Centre for Studies in Economics and Finance (CSEF), University of Naples, Italy.
- Eric Langlais & Andreea Cosnita-Langlais & Tim Friehe, 2024.
"Product Liability Influences Incentives for Horizontal Mergers,"
Working Papers
hal-04516113, HAL.
- Eric Langlais & Andreea Cosnita-Langlais & Tim Friehe, 2024. "Product Liability Influences Incentives for Horizontal Mergers," EconomiX Working Papers 2024-10, University of Paris Nanterre, EconomiX.
- Raymond J. March, 2021. "The FDA and the COVID‐19: A political economy perspective," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1210-1228, April.
- Giovanni Immordino & Michele Polo, 2014.
"Public Policies in Investment-Intensive Industries,"
World Scientific Book Chapters, in: Martin Peitz & Yossi Spiegel (ed.), THE ANALYSIS OF COMPETITION POLICY AND SECTORAL REGULATION, chapter 13, pages 365-388,
World Scientific Publishing Co. Pte. Ltd..
- Giovanni Immordino & Michele Polo, 2013. "Public Policies in Investment Intensive Industries," Working Papers 507, IGIER (Innocenzo Gasparini Institute for Economic Research), Bocconi University.
- Giovanni Immordino & Michele Polo, 2013. "Public Policies in Investment Intensive Industries," IEFE Working Papers 59, IEFE, Center for Research on Energy and Environmental Economics and Policy, Universita' Bocconi, Milano, Italy.
- Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric C. Sun & Dana Goldman, 2009.
"The Effects of Product Liability Exemption in the Presence of the FDA,"
NBER Working Papers
15603, National Bureau of Economic Research, Inc.
- Tomas J. Philipson & Eric Sun & Dana Goldman, 2010. "The Effects of Product Liability Exemption in the Presence of the FDA," NBER Chapters, in: Regulation vs. Litigation: Perspectives from Economics and Law, pages 137-163, National Bureau of Economic Research, Inc.
- Apostolos Tsiachristas† & Ren頇oudriaan & Wim Groot, 2013. "The welfare effects of innovative pharmaceuticals: an international perspective from the Dutch experience," Applied Economics, Taylor & Francis Journals, vol. 45(9), pages 1219-1226, March.
- John Romley & Tiffany Shih, 2017. "Product safety spillovers and market viability for biologic drugs," International Journal of Health Economics and Management, Springer, vol. 17(2), pages 135-158, June.
- Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
- Tomas J. Philipson & George Zanjani, 2013. "Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension," NBER Working Papers 19005, National Bureau of Economic Research, Inc.
- Sebastian Calónico & Rafael Di Tella & Juan Cruz Lopez del Valle, 2023. "The Political Economy of a “Miracle Cure”: The Case of Nebulized Ibuprofen and its Diffusion in Argentina," NBER Working Papers 31781, National Bureau of Economic Research, Inc.
- Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-chong, 2023.
"Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis,"
Journal of Macroeconomics, Elsevier, vol. 76(C).
- Hu, Mei-Ying & Lu, You-Xun & Lai, Ching-Chong, 2022. "Patent term extensions and commercialization lags in the pharmaceutical industry: A growth-theoretic analysis," MPRA Paper 113923, University Library of Munich, Germany.
- Clifford Winston, 2008. "The Efficacy of Information Policy: A Review of Archon Fung, Mary Graham, and David Weil's Full Disclosure: The Perils and Promise of Transparency," Journal of Economic Literature, American Economic Association, vol. 46(3), pages 704-717, September.
- Gayle DeLong, 2018. "Is “Delitigation” Associated with a Change in Product Safety? The Case of Vaccines," Review of Industrial Organization, Springer;The Industrial Organization Society, vol. 52(1), pages 1-53, February.
Articles
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010.
"An economic evaluation of the war on cancer,"
Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
See citations under working paper version above.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.
- Sun Eric & Jena Anupam B & Lakdawalla Darius & Reyes Carolina & Philipson Tomas J & Goldman Dana, 2010.
"The Contributions of Improved Therapy and Earlier Detection to Cancer Survival Gains, 1988-2000,"
Forum for Health Economics & Policy, De Gruyter, vol. 13(2), pages 1-22, February.
Cited by:
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010.
"An economic evaluation of the war on cancer,"
Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
- Eric C. Sun & Anupam B. Jena & Darius N. Lakdawalla & Carolina M. Reyes & Tomas J. Philipson & Dana P. Goldman, 2009. "An Economic Evaluation of the War on Cancer," NBER Working Papers 15574, National Bureau of Economic Research, Inc.
- Fatih Safa Erenay & Oguzhan Alagoz & Ritesh Banerjee & Robert R. Cima, 2011. "Estimating the Unknown Parameters of the Natural History of Metachronous Colorectal Cancer Using Discrete-Event Simulation," Medical Decision Making, , vol. 31(4), pages 611-624, July.
- Adam Leive & Thomas Stratmann, 2015. "Do national cancer screening guidelines reduce mortality?," Journal of Population Economics, Springer;European Society for Population Economics, vol. 28(4), pages 1075-1095, October.
- David H. Howard & Peter B. Bach & Ernst R. Berndt & Rena M. Conti, 2015. "Pricing in the Market for Anticancer Drugs," NBER Working Papers 20867, National Bureau of Economic Research, Inc.
- Seabury Seth A. & Goldman Dana P. & Gupta Charu N. & Khan Zeba M. & Chandra Amitabh & Philipson Tomas J. & Lakdawalla Darius N., 2016. "Quantifying Gains in the War on Cancer Due to Improved Treatment and Earlier Detection," Forum for Health Economics & Policy, De Gruyter, vol. 19(1), pages 141-156, June.
- Lakdawalla, Darius N. & Sun, Eric C. & Jena, Anupam B. & Reyes, Carolina M. & Goldman, Dana P. & Philipson, Tomas J., 2010.
"An economic evaluation of the war on cancer,"
Journal of Health Economics, Elsevier, vol. 29(3), pages 333-346, May.
- Tomas J. Philipson & Eric Sun, 2008.
"Is the Food And Drug Administration Safe And Effective?,"
Journal of Economic Perspectives, American Economic Association, vol. 22(1), pages 85-102, Winter.
See citations under working paper version above.
- Philipson, Tomas J. & Sun, Eric, 2007. "Is the Food and Drug Administration Safe and Effective?," Working Papers 218, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
- Tomas J. Philipson & Eric Sun, 2007. "Is the Food and Drug Administration Safe and Effective?," NBER Working Papers 13561, National Bureau of Economic Research, Inc.
- Philipson, Tomas & Berndt, Ernst R. & Gottschalk, Adrian H.B. & Sun, Eric, 2008.
"Cost-benefit analysis of the FDA: The case of the prescription drug user fee acts,"
Journal of Public Economics, Elsevier, vol. 92(5-6), pages 1306-1325, June.
- Philipson, Tomas J. & Berndt, Ernst R. & Gottschalk, Adrian H. B. & Sun, Eric, 2007. "Cost-Benefit Analysis of the FDA: The Case of the Prescription Drug User Fee Acts," Working Papers 217, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State.
Cited by:
- Chorniy, Anna & Bailey, James & Maloney, Michael & Civan, Abdulkadir, 2019. "Regulatory Review Time and Pharmaceutical R&D," Working Papers 06923, George Mason University, Mercatus Center.
- Matthew Grennan & Robert Town, 2015.
"Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices,"
NBER Working Papers
20981, National Bureau of Economic Research, Inc.
- Matthew Grennan & Robert J. Town, 2020. "Regulating Innovation with Uncertain Quality: Information, Risk, and Access in Medical Devices," American Economic Review, American Economic Association, vol. 110(1), pages 120-161, January.
- Daniel R. Wilmoth, 2015. "Reconciling Estimates of the Value to Firms of Reduced Regulatory Delay in the Marketing of Their New Drugs," Health Economics, John Wiley & Sons, Ltd., vol. 24(12), pages 1651-1656, December.
- Raymond J. March, 2021. "The FDA and the COVID‐19: A political economy perspective," Southern Economic Journal, John Wiley & Sons, vol. 87(4), pages 1210-1228, April.
- Anna Chorniy & James Bailey & Abdulkadir Civan & Michael Maloney, 2021. "Regulatory review time and pharmaceutical research and development," Health Economics, John Wiley & Sons, Ltd., vol. 30(1), pages 113-128, January.
- Philipson Tomas J. & Sun Eric & Goldman Dana & Jena Anupam B., 2012. "A Reexamination of the Costs of Medical R&D Regulation," Forum for Health Economics & Policy, De Gruyter, vol. 15(1), pages 1-28, October.
- Casey B. Mulligan, 2021. "Peltzman Revisited: Quantifying 21st Century Opportunity Costs of FDA Regulation," NBER Working Papers 29574, National Bureau of Economic Research, Inc.
- Mary Olson, 2013. "Eliminating the U.S. drug lag: Implications for drug safety," Journal of Risk and Uncertainty, Springer, vol. 47(1), pages 1-30, August.
- Ilke Onur & Magnus Söderberg, 2020. "The impact of regulatory review time on incremental and radical innovation: evidence from the high-risk medical device market," Journal of Regulatory Economics, Springer, vol. 57(2), pages 134-158, April.
- Tomas J. Philipson & George Zanjani, 2013. "Economic Analysis of Risk and Uncertainty induced by Health Shocks: A Review and Extension," NBER Working Papers 19005, National Bureau of Economic Research, Inc.
- Samuel DeCanio, 2024. "Cost benefit analysis and the FDA: measuring the costs and benefits of drug approval under the PDUFA I-II, 1998–2005," Journal of Regulatory Economics, Springer, vol. 66(2), pages 174-180, December.
- Tannista Banerjee & Arnab Nayak, 2017. "Why trash don’t pass? pharmaceutical licensing and safety performance of drugs," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 18(1), pages 59-71, January.
- Kristopher J. Hult & Tomas J. Philipson, 2012. "Public Liabilities and Health Care Policy," NBER Working Papers 18571, National Bureau of Economic Research, Inc.
- Henry Grabowski & Y. Richard Wang, 2008. "Do Faster Food and Drug Administration Drug Reviews Adversely Affect Patient Safety? An Analysis of the 1992 Prescription Drug User Fee Act," Journal of Law and Economics, University of Chicago Press, vol. 51(2), pages 377-406, May.
- Glenn L. Furton, 2023. "The pox of politics: Troesken’s tradeoff reexamined," Public Choice, Springer, vol. 195(1), pages 169-191, April.
Chapters
- Tomas J. Philipson & Eric Sun & Dana Goldman, 2010.
"The Effects of Product Liability Exemption in the Presence of the FDA,"
NBER Chapters, in: Regulation vs. Litigation: Perspectives from Economics and Law, pages 137-163,
National Bureau of Economic Research, Inc.
See citations under working paper version above.Sorry, no citations of chapters recorded.
- Tomas J. Philipson & Eric C. Sun & Dana Goldman, 2009. "The Effects of Product Liability Exemption in the Presence of the FDA," NBER Working Papers 15603, National Bureau of Economic Research, Inc.
More information
Research fields, statistics, top rankings, if available.Statistics
Access and download statistics for all items
Co-authorship network on CollEc
NEP Fields
NEP is an announcement service for new working papers, with a weekly report in each of many fields. This author has had 3 papers announced in NEP. These are the fields, ordered by number of announcements, along with their dates. If the author is listed in the directory of specialists for this field, a link is also provided.- NEP-HEA: Health Economics (3) 2007-11-03 2008-07-14 2009-12-19
- NEP-AGR: Agricultural Economics (1) 2007-11-03
- NEP-HAP: Economics of Happiness (1) 2008-07-14
- NEP-REG: Regulation (1) 2007-11-03
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.
To update listings or check citations waiting for approval, Eric Sun should log into the RePEc Author Service.
To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.
To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.
Please note that most corrections can take a couple of weeks to filter through the various RePEc services.